{"success":true,"data":{"pressRelease":{"id":"157055","rtpr_id":"nGNX89Jh1f-20260930","ticker":"BBNX","exchange":"NASDAQ","all_tickers":["BBNX"],"title":"Beta Bionics (BBNX) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before November 3, 2026 Lead Plaintiff Deadline","author":"Globe Newswire","published_at":"2026-09-30T15:12:59.088Z","article_body":"SAN FRANCISCO, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:\nBBNX) faces a securities class action, which seeks to represent investors who\npurchased or otherwise acquired shares of the company’s common stock between\nJuly 30, 2025 and February 24, 2026.\n\nThe lawsuit follows a series of surprise revelations about the FDA’s\nconcerns over company’s automated insulin delivery system (“iLet”), each\nof which sent the price of Beta Bionics shares sharply lower.\n\nNational shareholders rights firm Hagens Berman is investigating claims that\nBeta Bionics violated the federal securities laws and encourages Beta Bionics\ninvestors who suffered substantial losses to submit your losses now\n(https://www.globenewswire.com/Tracker?data=AsjTuefqAc7APE31-a6zwFRFJ096apTZiPXsZepQGpKGnAMxFtgg8dmsI1goSdzxBtBbexcNViFWYANVSPm_A1BUYTYZiABkB3LZBq8-ECBBtroNRW_Hs5HKodOR-JsRURD4M_S6j6jGCyB5KMSG_5ayQlQJtB7uj503yHQ1jWU=).\n\nClass Period: July 30, 2025 – Feb. 24, 2026\nLead Plaintiff Deadline: Nov. 3, 2026\nVisit: www.hbsslaw.com/bbnx \nDirect Contact Email: BBNX@hbsslaw.com \nFirm Telephone: 844-916-0895\n\nBeta Bionics (BBNX) Securities Class Action:\n\nDuring the Class Period, the company and its management heavily promoted its\niLet medical device as demanding “the least engagement from the user” and\ndelivering “the most automated adaptation of any” automated insulin\ndelivery system. Beta Bionics also assured investors that healthcare\nprofessionals “are seeing good results from their patients and becoming more\ncomfortable prescribing the iLet[.]”\n\nOn October 28, 2025, Beta Bionics’ management discussed their receipt of a\nForm 483 from the FDA after its inspection of Beta Bionics’ iLet\nmanufacturing, they called the 483 “primarily related to our customer\ncomplaint handling system,” downplayed the inspection as “not unusual in\nour industry,” and said “[w]e’re confident that our new complaint\nhandling system and reporting system meets or exceeds the expectations laid\nout by the agency in their Form 483 observations.” CEO Sean Saint emphasized\n“[t]he 483 itself had nothing to do with the actual complaints being\nreceived[….] It had to do solely with the definition the reports being filed\nas complaints, and that’s all.”\n\nThe complaint alleges these and other statements misled investors because,\nunknown to them, Beta Bionics concealed its receipt of thousands of iLet\nsafety complaints, including numerous life-threatening hypoglycemic events,\nand failed to investigate or report the events to the FDA as it was required\nto do.\n\nBy February 24, 2026, when the FDA published its January 28, 2026 WARNING\nLETTER to CEO Saint, investors learned the truth. The FDA, citing its\ninspection, was brutal:\n* “Your firm failed to adequately analyze quality data, such as complaints,\nto identify existing and potential causes of nonconforming product or other\nquality problems[;]”\n* “Your firm failed to implement corrective and preventative actions […]\nfor complaints related to device malfunctions that led to serious adverse\nhealth outcomes[;]” and\n* “Significant violations include […] [f]ailure to report to the FDA\ninformation […] no later than 30 calendar days after the day that your firm\nreceived or otherwise became aware of information, from any source, that\nreasonably suggests that a device that it markets may have caused or\ncontributed to a death or serious injury[.]”\n“We’re focused on whether Beta Bionics may have intentionally misled\ninvestors by placing revenues ahead of patient safety,” said Reed Kathrein\n(https://www.globenewswire.com/Tracker?data=HuJ3mxFX-YA9PxDurWeNXrMhtNUhwawV-amUKwlGR_gYZEyKza0GjuUhZqmYDeQuQPWRFawgPNqS2Ta7fysoSQ5Dd7kXP9Wm53ULeCiWlzRtU4Mt_2GX9QzWw-S-iqH8),\nthe Hagens Berman partner leading the firm’s investigation.\n\nIf you invested in Beta Bionics and have substantial losses, or have knowledge\nthat will assist the firm’s investigation, submit your losses now\n(https://www.globenewswire.com/Tracker?data=AsjTuefqAc7APE31-a6zwFRFJ096apTZiPXsZepQGpI-CRrCQZbEJwIPUq-2xFCnOAUaW3smFJHqd-JapXXhgGcWGiP4VGd9Q2tDydegiknE6K0Nf5SumT8P18Mo0CwZRPZtIXYCKuimVFMGxLRUcP2BGWyYgT4vRBE92JYoD8Y=)\n»\n\nWhistleblowers: Persons with non-public information regarding Beta Bionics\nshould consider their options to help in the investigation or take advantage\nof the SEC Whistleblower program. Under the new program, whistleblowers who\nprovide original information may receive rewards totaling up to 30 percent of\nany successful recovery made by the SEC. For more information, call Reed\nKathrein at 844-916-0895 or email BBNX@hbsslaw.com.\n\nAbout Hagens Berman\n(https://www.globenewswire.com/Tracker?data=oKupyrsU3oZwfvD0BAoEdwqWAojAfWGL8GCFQofPT2a7jssNj3d70ptuOYDDNsO8TwekLeMu3_yAkJns3pLEkZIux7JkeuQ00B-aUY_OqmE=)\nHagens Berman is a global plaintiffs’ rights complex litigation firm\nfocusing on corporate accountability. The firm is home to a robust practice\nand represents investors as well as whistleblowers, workers, consumers and\nothers in cases achieving real results for those harmed by corporate\nnegligence and other wrongdoings. Hagens Berman’s team has secured more than\n$2.9 billion in this area of law. More about the firm and its successes can be\nfound at hbsslaw.com\n(https://www.globenewswire.com/Tracker?data=EnXH-ZcLFyMJ-rcfoujkRcEVET5zxjXRhb7iFdd7vjDGVoSR5ZYzzPYSkF3vx_tEiHmmuEcJD3miTRSfK_ND4w==).\nFollow the firm for updates and news at @ClassActionLaw. \n\nAttorney Advertising. Prior results do not guarantee a similar outcome in any\nfuture case.\n\nContact: Hagens Berman, Reed Kathrein, 715 Hearst Avenue, Suite 300,\nBerkeley, CA 94710, 844-916-0895, BBNX@hbsslaw.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/2c81cd72-0ffb-43c9-9d0f-b622c3e44e43)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX89Jh1f-20260930","title":"Beta Bionics (BBNX) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before November 3, 2026 Lead Plaintiff Deadline","author":"Globe Newswire","ticker":"BBNX","created":"2026-09-30T15:12:59.088Z","tickers":["BBNX"],"exchange":"NASDAQ","article_body":"SAN FRANCISCO, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:\nBBNX) faces a securities class action, which seeks to represent investors who\npurchased or otherwise acquired shares of the company’s common stock between\nJuly 30, 2025 and February 24, 2026.\n\nThe lawsuit follows a series of surprise revelations about the FDA’s\nconcerns over company’s automated insulin delivery system (“iLet”), each\nof which sent the price of Beta Bionics shares sharply lower.\n\nNational shareholders rights firm Hagens Berman is investigating claims that\nBeta Bionics violated the federal securities laws and encourages Beta Bionics\ninvestors who suffered substantial losses to submit your losses now\n(https://www.globenewswire.com/Tracker?data=AsjTuefqAc7APE31-a6zwFRFJ096apTZiPXsZepQGpKGnAMxFtgg8dmsI1goSdzxBtBbexcNViFWYANVSPm_A1BUYTYZiABkB3LZBq8-ECBBtroNRW_Hs5HKodOR-JsRURD4M_S6j6jGCyB5KMSG_5ayQlQJtB7uj503yHQ1jWU=).\n\nClass Period: July 30, 2025 – Feb. 24, 2026\nLead Plaintiff Deadline: Nov. 3, 2026\nVisit: www.hbsslaw.com/bbnx \nDirect Contact Email: BBNX@hbsslaw.com \nFirm Telephone: 844-916-0895\n\nBeta Bionics (BBNX) Securities Class Action:\n\nDuring the Class Period, the company and its management heavily promoted its\niLet medical device as demanding “the least engagement from the user” and\ndelivering “the most automated adaptation of any” automated insulin\ndelivery system. Beta Bionics also assured investors that healthcare\nprofessionals “are seeing good results from their patients and becoming more\ncomfortable prescribing the iLet[.]”\n\nOn October 28, 2025, Beta Bionics’ management discussed their receipt of a\nForm 483 from the FDA after its inspection of Beta Bionics’ iLet\nmanufacturing, they called the 483 “primarily related to our customer\ncomplaint handling system,” downplayed the inspection as “not unusual in\nour industry,” and said “[w]e’re confident that our new complaint\nhandling system and reporting system meets or exceeds the expectations laid\nout by the agency in their Form 483 observations.” CEO Sean Saint emphasized\n“[t]he 483 itself had nothing to do with the actual complaints being\nreceived[….] It had to do solely with the definition the reports being filed\nas complaints, and that’s all.”\n\nThe complaint alleges these and other statements misled investors because,\nunknown to them, Beta Bionics concealed its receipt of thousands of iLet\nsafety complaints, including numerous life-threatening hypoglycemic events,\nand failed to investigate or report the events to the FDA as it was required\nto do.\n\nBy February 24, 2026, when the FDA published its January 28, 2026 WARNING\nLETTER to CEO Saint, investors learned the truth. The FDA, citing its\ninspection, was brutal:\n* “Your firm failed to adequately analyze quality data, such as complaints,\nto identify existing and potential causes of nonconforming product or other\nquality problems[;]”\n* “Your firm failed to implement corrective and preventative actions […]\nfor complaints related to device malfunctions that led to serious adverse\nhealth outcomes[;]” and\n* “Significant violations include […] [f]ailure to report to the FDA\ninformation […] no later than 30 calendar days after the day that your firm\nreceived or otherwise became aware of information, from any source, that\nreasonably suggests that a device that it markets may have caused or\ncontributed to a death or serious injury[.]”\n“We’re focused on whether Beta Bionics may have intentionally misled\ninvestors by placing revenues ahead of patient safety,” said Reed Kathrein\n(https://www.globenewswire.com/Tracker?data=HuJ3mxFX-YA9PxDurWeNXrMhtNUhwawV-amUKwlGR_gYZEyKza0GjuUhZqmYDeQuQPWRFawgPNqS2Ta7fysoSQ5Dd7kXP9Wm53ULeCiWlzRtU4Mt_2GX9QzWw-S-iqH8),\nthe Hagens Berman partner leading the firm’s investigation.\n\nIf you invested in Beta Bionics and have substantial losses, or have knowledge\nthat will assist the firm’s investigation, submit your losses now\n(https://www.globenewswire.com/Tracker?data=AsjTuefqAc7APE31-a6zwFRFJ096apTZiPXsZepQGpI-CRrCQZbEJwIPUq-2xFCnOAUaW3smFJHqd-JapXXhgGcWGiP4VGd9Q2tDydegiknE6K0Nf5SumT8P18Mo0CwZRPZtIXYCKuimVFMGxLRUcP2BGWyYgT4vRBE92JYoD8Y=)\n»\n\nWhistleblowers: Persons with non-public information regarding Beta Bionics\nshould consider their options to help in the investigation or take advantage\nof the SEC Whistleblower program. Under the new program, whistleblowers who\nprovide original information may receive rewards totaling up to 30 percent of\nany successful recovery made by the SEC. For more information, call Reed\nKathrein at 844-916-0895 or email BBNX@hbsslaw.com.\n\nAbout Hagens Berman\n(https://www.globenewswire.com/Tracker?data=oKupyrsU3oZwfvD0BAoEdwqWAojAfWGL8GCFQofPT2a7jssNj3d70ptuOYDDNsO8TwekLeMu3_yAkJns3pLEkZIux7JkeuQ00B-aUY_OqmE=)\nHagens Berman is a global plaintiffs’ rights complex litigation firm\nfocusing on corporate accountability. The firm is home to a robust practice\nand represents investors as well as whistleblowers, workers, consumers and\nothers in cases achieving real results for those harmed by corporate\nnegligence and other wrongdoings. Hagens Berman’s team has secured more than\n$2.9 billion in this area of law. More about the firm and its successes can be\nfound at hbsslaw.com\n(https://www.globenewswire.com/Tracker?data=EnXH-ZcLFyMJ-rcfoujkRcEVET5zxjXRhb7iFdd7vjDGVoSR5ZYzzPYSkF3vx_tEiHmmuEcJD3miTRSfK_ND4w==).\nFollow the firm for updates and news at @ClassActionLaw. \n\nAttorney Advertising. Prior results do not guarantee a similar outcome in any\nfuture case.\n\nContact: Hagens Berman, Reed Kathrein, 715 Hearst Avenue, Suite 300,\nBerkeley, CA 94710, 844-916-0895, BBNX@hbsslaw.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/2c81cd72-0ffb-43c9-9d0f-b622c3e44e43)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-30T15:12:59.136622241Z","server_sent_at_ms":1790781179136},"received_at":"2026-09-30T15:12:59.188Z","source_url":null},"analysis":{"id":"145730","press_release_id":"157055","analysis_json":{"redFlags":["FDA warning letter issued to CEO citing failure to report serious adverse device events","alleged concealment of thousands of iLet safety complaints, including life-threatening hypoglycemic events","pending securities class action with Nov. 3, 2026 lead plaintiff deadline"],"eventType":"legal_litigation","narrative":"Hagens Berman announced a securities fraud class action against Beta Bionics covering purchasers of BBNX shares between July 30, 2025 and February 24, 2026, with a lead plaintiff deadline of November 3, 2026.\n\nThe complaint alleges the company concealed thousands of iLet safety complaints, including life-threatening hypoglycemic events, and failed to report them to the FDA as required.\n\nThe release is law-firm solicitation seeking investors with losses; the underlying FDA Form 483 and January 2026 warning letter were already public, so this adds no new issuer disclosure.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm class-action solicitation on already-disclosed FDA issues -- suppress."},"keyFigures":{},"quotedText":"We're focused on whether Beta Bionics may have intentionally misled investors by placing revenues ahead of patient safety","namedEntities":{"people":[{"name":"Sean Saint","role":"CEO of Beta Bionics"},{"name":"Reed Kathrein","role":"Hagens Berman partner leading investigation"}],"products":["iLet"],"companies":[{"name":"Beta Bionics, Inc.","ticker":"BBNX","relationship":"target of class action"},{"name":"Hagens Berman","relationship":"plaintiff law firm"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"}],"dollarAmounts":[{"amount":"$2.9 billion","context":"Hagens Berman's cumulative recoveries in this area of law"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm (Hagens Berman) solicitation for a securities class action; no certified class or settlement announced. The underlying FDA issues are already public, so this is low-signal noise despite the allegations."},"tickerRelevance":{"others":[],"primary":"BBNX"},"globalImportance":20,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"underlyingRegulatoryRisk":"FDA warning letter already public"}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Hagens Berman announced a securities fraud class action against Beta Bionics covering purchasers of BBNX shares between July 30, 2025 and February 24, 2026, with a lead plaintiff deadline of November 3, 2026.\n\nThe complaint alleges the company concealed thousands of iLet safety complaints, including life-threatening hypoglycemic events, and failed to report them to the FDA as required.\n\nThe release is law-firm solicitation seeking investors with losses; the underlying FDA Form 483 and January 2026 warning letter were already public, so this adds no new issuer disclosure.","key_figures":{},"named_entities":{"people":[{"name":"Sean Saint","role":"CEO of Beta Bionics"},{"name":"Reed Kathrein","role":"Hagens Berman partner leading investigation"}],"products":["iLet"],"companies":[{"name":"Beta Bionics, Inc.","ticker":"BBNX","relationship":"target of class action"},{"name":"Hagens Berman","relationship":"plaintiff law firm"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"}],"dollarAmounts":[{"amount":"$2.9 billion","context":"Hagens Berman's cumulative recoveries in this area of law"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-30T15:13:03.864Z","global_importance":20,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"underlyingRegulatoryRisk":"FDA warning letter already public"}},"durationMs":4662,"modelName":"glm-5.3-flashx"}}